Online citations, reference lists, and bibliographies.
← Back to Search

Initial Evaluation Of Diaspirin Cross-linked Hemoglobin (DCLHb) As A Vasopressor In Critically Ill Patients.

G. Reah, A. Bodenham, A. Mallick, E. K. Daily, R. Przybelski
Published 1997 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To evaluate the hemodynamic effects and any toxicologic effects of diaspirin cross-linked hemoglobin (DCLHb) in critically ill patients. DESIGN A prospective, observational study. SETTING A seven-bed intensive care unit (ICU) in a University teaching hospital. PATIENTS Fourteen critically ill patients requiring vasopressor therapy to maintain adequate mean arterial pressure (MAP). All patients had secondary organ dysfunction. INTERVENTIONS Administration of 100 mL boluses of 10% diaspirin cross-linked hemoglobin, up to a maximum of 500 mL, given over 15 mins and separated by 60 to 90 mins. MEASUREMENTS AND MAIN RESULTS Hemodynamic parameters, norepinephrine and inotropic requirements, arterial and mixed venous blood gases, urine output, and biochemical and hematologic analyses were measured before diaspirin cross-linked hemoglobin administration and at multiple time points up to 72 hrs. MAP was maintained at approximately preinfusion values and the reduction in norepinephrine requirements was used as the main end point to assess the efficacy of diaspirin cross-linked hemoglobin as a vasopressor. Diaspirin cross-linked hemoglobin demonstrated a marked vasopressor action, allowing norepinephrine requirements to be reduced from 0.29 +/- 0.15 (SD) microgram/kg/min to 0.15 +/- 0.14 and 0.07 +/- 0.10 microgram/kg/min after the first (at 1.5 hrs, p < .001) and last (at 7.5 hrs, p < .0001) boluses, respectively. These reductions in norepinephrine requirements were maintained at 24, 48, and 72 hrs (p < .01 at all time points). These hemodynamic changes began within 5 mins of starting the diaspirin cross-linked hemoglobin infusion. MAP, heart rate, central venous pressure, pulmonary artery occlusion pressure, mean pulmonary arterial pressure (MPAP), systemic vascular resistance index, and urine output did not demonstrate any significant changes from preinfusion values. Pulmonary vascular resistance index increased at 7.5 hrs despite nonsignificant increases in MPAP. Cardiac index and oxygen delivery index decreased significantly at 7.5 hrs and 24 hrs. Total plasma bilirubin increased significantly from baseline at 24 and 48 hrs, before returning to baseline values within 5 days. Platelet count was significantly reduced at 6 and 24 hrs. No other biochemical or hematologic analyses were altered significantly post diaspirin cross-linked hemoglobin. CONCLUSIONS This preliminary study demonstrated that diaspirin cross-linked hemoglobin is a potent vasopressor agent in critically ill patients with septicemic shock or systemic inflammatory response syndrome. This vasopressor characteristic of diaspirin cross-linked hemoglobin may have future clinical applications.
This paper references
10.1177/106002809502900108
Use of Nitric Oxide Synthase Inhibitors as a Novel Treatment for Septic Shock
T. A. Wolfe (1995)
10.1097/00003246-199305000-00021
Role of nitric oxide in the hemodynamic changes of sepsis
J. A. Lorente (1993)
10.1097/00000542-199302000-00018
Focal Cerebral Ischemia in Rats: Effect of Hypervolemic Hemodilution with Diaspirin Cross‐linked Hemoglobin Versus Albumin on Brain Injury and Edema
D. Cole (1993)
10.1097/00005373-199412000-00043
Diaspirin cross-linked hemoglobin is efficacious in gut resuscitation as measured by a GI tract optode.
H. Frankel (1996)
10.1016/0024-3205(94)00566-4
Effect of stroma-free hemoglobin and diaspirin cross-linked hemoglobin on the regional circulation and systemic hemodynamics.
A. Gulati (1994)
Role of adrenergic mechanisms in the pressor effect of diaspirin cross-linked hemoglobin.
A. Gulati (1994)
10.1016/0024-3205(96)00269-X
Norepinephrine release during vasoconstriction induced by cross-linked hemoglobin.
L. Hunter (1996)
10.1097/00003246-199505000-00016
Yohimbine modulates diaspirin crosslinked hemoglobin-induced systemic hemodynamics and regional circulatory effects.
A. Sharma (1995)
10.1097/00024382-199506000-00052
THE EFFECTS OF DIASPIRIN CROSS‐LINKED HEMOGLOBIN IN SEPSIS
M. G. Mourelatos (1996)
Cross-linked hemoglobin solution as a resuscitative fluid after hemorrhage in the rat.
Przybelski Rj (1991)
10.3109/10731199409117396
Nitric Oxide Mediates the Hypertensive Response to a Modified Hemoglobin Solution (DCLHBTH) in Rats
S. Katsuyama (1994)
A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin.
S. C. Schultz (1993)
10.1097/00005373-199310000-00019
Use of base deficit to compare resuscitation with lactated Ringer's solution, Haemaccel, whole blood, and diaspirin cross-linked hemoglobin following hemorrhage in rats.
S. C. Schultz (1993)
10.1097/00003246-199401000-00446
DIASPIRIN CROSS-LINKED HEMOGLOBIN (DCLHb???): PHASE I CLINICAL SAFETY ASSESSMENT IN NORMAL HEALTHY VOLUNTEERS
R. Przybelski (1994)
10.1097/00003246-199510000-00003
Nitric oxide inhibition in the treatment of septic shock.
Hata Js (1995)
10.3109/10731199509117978
Diaspirin crosslinked hemoglobin (DCLHb) attenuates bacterial translocation in rats.
S. C. Schultz (1995)
10.1016/0272-6386(95)90056-X
Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients.
S. Swan (1995)
10.1097/00003246-199507000-00006
Combined measurements of blood lactate concentrations and gastric intramucosal pH in patients with severe sepsis.
G. Friedman (1995)
10.1038/380221A0
S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control
L. Jia (1996)
10.1001/ARCHSURG.1994.01420260045005
Detrimental hemodynamic effects of nitric oxide synthase inhibition in septic shock.
F. M. Robertson (1994)
10.1016/S0140-6736(95)90168-X
Haemoglobin-based blood substitutes and sepsis
E. Griffiths (1995)
Effect of diaspirin cross-linked hemoglobin and norepinephrine on systemic hemodynamics and regional circulation in rats.
A. Sharma (1994)
10.1152/JAPPL.1993.74.4.1769
Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin.
J. Hess (1993)
10.1097/00003246-199612000-00011
Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution.
R. Przybelski (1996)
10.1097/00005373-199409000-00013
The efficacy of diaspirin crosslinked hemoglobin solution resuscitation in a model of uncontrolled hemorrhage.
S. C. Schultz (1994)
10.1378/CHEST.101.6.1644
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.
R. Bone (1992)
10.1097/00003246-198510000-00009
APACHE II: a severity of disease classification system.
W. Knaus (1985)
10.3109/10731199409117402
Characterization of the hemodynamic response to intravenous diaspirin crosslinked hemoglobin solution in rats.
D. Malcolm (1994)
10.1097/00003246-199601000-00023
Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin.
A. Gulati (1996)
10.1016/s0021-9258(18)67605-7
Isolation and characterization of a new hemoglobin derivative cross-linked between the alpha chains (lysine 99 alpha 1----lysine 99 alpha 2).
R. Chatterjee (1986)
Equilibrium oxygen binding to human hemoglobin cross-linked between the alpha chains by bis(3,5-dibromosalicyl) fumarate.
K. Vandegriff (1989)
Rat maze performance after resuscitation with cross-linked hemoglobin solution.
R. Przybelski (1990)
10.1016/0024-3205(94)90103-1
Prazosin blocks the pressor but not the regional circulatory effects of diaspirin crosslinked hemoglobin.
A. Gulati (1994)
10.1093/CVR/28.1.34
Effects of a nitric oxide synthase inhibitor in humans with septic shock.
A. Petros (1994)



This paper is referenced by
10.1152/ajpgi.1999.276.6.G1507
Effect of diaspirin cross-linked hemoglobin on normal and postischemic microcirculation of the rat pancreas.
E. von Dobschütz (1999)
10.1097/01.CCM.0000216188.79290.20
Can the effects of vasoactivity of molecular hemoglobin-based plasma expanders be ignored?
A. Tsai (2006)
10.1097/00000542-200003000-00007
Randomized Trial of Diaspirin Cross-linked Hemoglobin Solution as an Alternative to Blood Transfusion after Cardiac Surgery
M. Lamy (2000)
Die Effekte des künstlichen Sauerstoffträgers Diaspirin crosslinked hemoglobin auf die Mikrozirkulation des Pankreas
E. Dobschuetz (2002)
10.1097/00005373-200205000-00011
Post hoc mortality analysis on the efficacy trial of diaspirin cross-linked hemoglobin in the treatment of severe traumatic hemorrhagic shock.
C. G. Ward (2002)
10.1017/S1049023X14001174
Emergency Resuscitation of Patients Enrolled in the US Diaspirin Cross-linked Hemoglobin (DCLHb) Clinical Efficacy Trial.
E. Sloan (2015)
10.1074/JBC.274.4.2029
Reactions of Sperm Whale Myoglobin with Hydrogen Peroxide
A. Alayash (1999)
10.1016/j.jamcollsurg.2008.09.023
Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial.
E. Moore (2009)
10.1111/j.1537-2995.2009.02356.x
Hemoglobin‐based oxygen carriers: current status and future directions
Toby A Silverman (2009)
Peer Reviewed Title: Shock Index and Prediction of Traumatic Hemorrhagic Shock 28-Day Mortality: Data from the DCLHb Resuscitation Clinical Trials
B. William (2014)
10.1007/978-3-662-13450-4_22
Clinical Effects of Cell-Free Hemoglobin, a Scavenger of Nitric Oxide, in Septic Shock
R. Kilbourn (1997)
10.1152/JAPPLPHYSIOL.00049.2004
Contribution of nNOS- and eNOS-derived NO to microvascular smooth muscle NO exposure.
M. Kavdia (2004)
10.1097/00000539-200102000-00007
The effects of diaspirin cross-linked hemoglobin on the tone of human saphenous vein.
M. Forrest (2001)
10.1097/00044067-199902000-00008
The trauma triad of death: hypothermia, acidosis, and coagulopathy.
J. Mikhail (1999)
10.1023/A:1005964907344
The role of nitric oxide in interleukin-2 therapy induced hypotension
H. Shahidi (2004)
10.2174/187152510791698389
Low molecular weight compounds with transition metals as free radical scavengers and novel therapeutic agents.
A. Bencini (2010)
10.1006/BBRC.1998.9312
Autoxidation of pyridoxalated hemoglobin polyoxyethylene conjugate.
T. Talarico (1998)
10.1152/JAPPL.2002.92.1.343
Comparison of transfusion with DCLHb or pRBCs for treatment of intraoperative anemia in sheep.
L. Vane (2002)
Disorders of hemoglobin: Genetics, pathophysiology, and clinical management, second edition
M. Steinberg (2009)
10.1097/01.CCM.0000098037.40520.81
Hemoglobin solutions
J. Creteur (2003)
10.1517/13543784.12.2.139
Recent developments in the treatment of sepsis
V. Sharma (2003)
10.1159/000083141
Hemoglobin-Based Oxygen Carrier Distribution Inside Vascular Wall and Arterial Pressure Evolution: Is There a Relationship?
Y. Smani (2005)
10.3109/10731190903495694
Relative Roles of Heme-Irons and Globin-Thiols in the Genesis of Acellular Hemoglobin Mediated Vasoconstriction
H. Kim (2010)
10.1007/978-1-4612-1222-5_19
Nitric Oxide as a Modulator of Sepsis: Therapeutic Possibilities
A. Salyapongse (2000)
Verbesserte pankreatische Mikrozirkulation und verringerter Gewebeschaden durch therapeutische Intervention mit bovinem Hämoglobin im Rattenmodell einer schweren akuten Pankreatitis
J. Izbicki (2004)
10.1016/S0169-409X(99)00050-2
Site-specific modifications and toxicity of blood substitutes. The case of diaspirin cross-linked hemoglobin.
F. D'agnillo (2000)
10.1097/00005344-200001000-00011
Bovine polymerized hemoglobin increases cardiac oxygen consumption and alters myocardial substrate metabolism in conscious dogs: role of nitric oxide.
K. Loke (2000)
10.1001/JAMA.282.19.1857
Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial.
E. Sloan (1999)
10.1164/AJRCCM.164.2.2011028
Safeguarding patients in clinical trials with high mortality rates.
B. Freeman (2001)
10.1002/9781119975427.CH24
Crosslinked and Polymerized Hemoglobins as Potential Blood Substitutes
K. W. Olsen (2011)
10.1097/00003246-200007000-00107
Cross-linked hemoglobin and tumor necrosis factor response to endotoxemia.
A. Sielenkämper (2000)
Die periphere und zentrale Gewebeoxygenierung unter akuter isovolämer Hämodilution mit der bovinen Hämoglobinlösung HBOC-201 im Vergleich zu Hydroxyäthylstärke im Tiermodell
Universitätsklinikum Hamburg Eppendorf (2001)
See more
Semantic Scholar Logo Some data provided by SemanticScholar